Durvalumab with tremelimumab for limited stage small-cell lung cancer

Durvalumab in combination with tremelimumab is in clinical development for patients with limited
stage small cell lung cancer (LS-SCLC). SCLC is a fast-growing cancer that forms in the tissues of
the lung and may have spread to the area between the lungs or to the lymph nodes above the
collarbone. SCLC is described as limited if the cancer is contained in one lung, tissues between
the lungs and in nearby lymph nodes. Although most patients with LS-SCLC will respond to initial
treatment, the majority experience disease relapse.